AU2012342226B2 - 1,4- dihydropyridine derivatives with Hsp modulating activity - Google Patents

1,4- dihydropyridine derivatives with Hsp modulating activity Download PDF

Info

Publication number
AU2012342226B2
AU2012342226B2 AU2012342226A AU2012342226A AU2012342226B2 AU 2012342226 B2 AU2012342226 B2 AU 2012342226B2 AU 2012342226 A AU2012342226 A AU 2012342226A AU 2012342226 A AU2012342226 A AU 2012342226A AU 2012342226 B2 AU2012342226 B2 AU 2012342226B2
Authority
AU
Australia
Prior art keywords
dimethyl
group
dicarboxylate
dihydropyridine
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012342226A
Other languages
English (en)
Other versions
AU2012342226A1 (en
Inventor
Gabor Balogh
Sandor Bernath
Ferenc Fulop
Ibolya Horvath
Akos Hunya
Botond Penke
Zsolt Torok
Laszlo Vigh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AU2012342226A1 publication Critical patent/AU2012342226A1/en
Application granted granted Critical
Publication of AU2012342226B2 publication Critical patent/AU2012342226B2/en
Assigned to RICHTER GEDEON NYRT. reassignment RICHTER GEDEON NYRT. Request for Assignment Assignors: LIPIDART KUTATO FEJLESZTO ES TANACSADO KFT.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AU2012342226A 2011-11-24 2012-11-22 1,4- dihydropyridine derivatives with Hsp modulating activity Ceased AU2012342226B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUHUP1100646 2011-11-24
HUP1100646 2011-11-24
PCT/HU2012/000126 WO2013076516A1 (en) 2011-11-24 2012-11-22 1,4- dihydropyridine derivatives with hsp modulating activity

Publications (2)

Publication Number Publication Date
AU2012342226A1 AU2012342226A1 (en) 2014-06-19
AU2012342226B2 true AU2012342226B2 (en) 2017-09-28

Family

ID=89662327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012342226A Ceased AU2012342226B2 (en) 2011-11-24 2012-11-22 1,4- dihydropyridine derivatives with Hsp modulating activity

Country Status (8)

Country Link
US (2) US10258498B2 (zh)
EP (1) EP2782573B1 (zh)
JP (1) JP6073913B2 (zh)
CN (2) CN110606822A (zh)
AU (1) AU2012342226B2 (zh)
CA (1) CA2854252C (zh)
HU (1) HUE046668T2 (zh)
WO (1) WO2013076516A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258498B2 (en) 2011-11-24 2019-04-16 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with Hsp modulating activity
WO2018156883A1 (en) * 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
CN109721596B (zh) * 2017-10-27 2020-12-18 广东东阳光药业有限公司 苯基取代的二氢吡啶类化合物及其用途
CN112930178A (zh) * 2018-07-12 2021-06-08 得克萨斯农业及机械体系综合大学 用于治疗铜缺乏的组合物和使用方法
CN115385850B (zh) * 2022-05-26 2023-10-20 昆明理工大学 一种1,4-二氢吡啶化合物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430094A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 3,5-Dicarbonsäureester-1,4-Dihydropyridinen als Arzneimittel
EP0717036A1 (de) * 1994-12-16 1996-06-19 Bayer Ag Verwendung von 5-Acyl-1,4-dihydropyridin zur Bekämpfung von Erkrankung des ZNS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1923990C3 (de) * 1969-05-10 1978-11-23 Bayer Ag Verfahren zur Herstellung von N-substituierten M-Dihydropyridin-S.S-dicarbonsäureestern
DE2210672C3 (de) * 1972-03-06 1980-03-20 Bayer Ag, 5090 Leverkusen N-substituierte unsymmetrische 1 ^-Dihydropyridin-S^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
JPS5547656A (en) * 1978-09-29 1980-04-04 Dainippon Pharmaceut Co Ltd 2-(2-substituted aminoethyl)-1,4-dihydropyridine derivative and its derivative
US4780538A (en) * 1986-02-12 1988-10-25 Merck & Co., Inc. Process for 1,4-dihydropyridine compounds using a titanamine catalyst
JPH01316357A (ja) * 1988-02-24 1989-12-21 Ajinomoto Co Inc 癌耐性克服剤及び新規１，４‐ジヒドロピリジン誘導体
EP0330470A3 (en) 1988-02-24 1992-01-02 Ajinomoto Co., Inc. 1,4-dihydropyridine derivatives useful against tumour cells
DE4011695A1 (de) 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
GB9119983D0 (en) * 1991-09-19 1991-11-06 Erba Carlo Spa Dihydropyridine derivatives useful in antitumor therapy
DE4200714A1 (de) * 1992-01-14 1993-07-15 Bayer Ag Spezieller 1,4-dihydropyridin-3,5-dicarbonsaeureester, verfahren zu seiner herstellung und seine pharmazeutische verwendung
DE4328884A1 (de) * 1993-08-27 1995-03-02 Bayer Ag Verwendung von N-alkylierten 1,4-Dihydropyridincarbonsäureestern als Arzneimittel
LV12200B (lv) 1997-07-03 1999-04-20 Gunārs DUBURS Antidiabētisks līdzeklis
US6306853B1 (en) 1998-02-10 2001-10-23 Nikken Chemicals Co., Ltd. 1,4-Dihydropyridine derivatives
WO2003086383A1 (en) 2002-04-12 2003-10-23 Multimmune Gmbh Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents
GB0306907D0 (en) * 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
TW200528107A (en) 2003-11-25 2005-09-01 Nissan Chemical Ind Ltd T-type calcium channel inhibitor
JP2007230869A (ja) * 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
US20060188938A1 (en) * 2005-01-07 2006-08-24 Mullan Michael J Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
US7851431B2 (en) 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
JP2011526925A (ja) * 2008-07-01 2011-10-20 ザカロン ファーマシューティカルズ，インク． ヘパラン硫酸阻害剤
CN101897705B (zh) * 2009-05-27 2014-04-09 中国科学院上海生命科学研究院 具有抗肿瘤活性的化合物
US10258498B2 (en) 2011-11-24 2019-04-16 Richter Gedeon Nyrt. 1,4-dihydropyridine derivatives with Hsp modulating activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430094A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 3,5-Dicarbonsäureester-1,4-Dihydropyridinen als Arzneimittel
EP0717036A1 (de) * 1994-12-16 1996-06-19 Bayer Ag Verwendung von 5-Acyl-1,4-dihydropyridin zur Bekämpfung von Erkrankung des ZNS

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAS RN 103026-84-2, STN Entry Date 04 Jul 1986 *
CAS RN 109329-68-2, STN Entry Date 18 Jul 1987 *
CAS RN 137887-45-7, STN Entry Date 13 Dec 1991 *
CAS RN 30594-37-7, STN Entry Date 16 Nov 1984 *
CAS RN 312595-85-0, STN Entry Date 03 Jan 2001 *
CAS RN 312598-61-1, STN Entry Date 03 Jan 2001 *
CAS RN 312696-73-4, STN Entry Date 04 Jan 2001 *
CAS RN 312698-14-9, STN Entry Date 04 Jan 2001 *
CAS RN 329780-01-0, STN Entry Date 03 April 2001 *
CAS RN 423141-44-0, STN Entry Date 30 May 2002 *
CAS RN 70008-26-3, STN Entry Date 16 Nov 1984 *

Also Published As

Publication number Publication date
WO2013076516A1 (en) 2013-05-30
JP2014533717A (ja) 2014-12-15
HUE046668T2 (hu) 2020-03-30
US10258498B2 (en) 2019-04-16
CA2854252C (en) 2016-11-29
CN103998038A (zh) 2014-08-20
US10660789B2 (en) 2020-05-26
CN110606822A (zh) 2019-12-24
AU2012342226A1 (en) 2014-06-19
EP2782573B1 (en) 2019-10-09
EP2782573A1 (en) 2014-10-01
CA2854252A1 (en) 2013-05-30
US20190192336A1 (en) 2019-06-27
JP6073913B2 (ja) 2017-02-01
US20140315893A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
US10660789B2 (en) 1,4-dihydropyridine derivatives with HSP modulating activity
Carmo Carreiras et al. The multifactorial nature of Alzheimer’s disease for developing potential therapeutics
Anand et al. Therapeutics of Alzheimer's disease: Past, present and future
CN109563047A (zh) 含有硅原子的依伐卡托类似物
Rampa et al. Hybrid-based multi-target ligands for the treatment of Alzheimer's disease
WO2008150899A1 (en) Combination therapies for treatment of cancer and inflammatory diseases
EA026559B1 (ru) Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1
EP2620429A1 (en) Hydroxylamine compounds and methods of their use
JP6208122B2 (ja) プロテオスタシス調節因子
Lin et al. Therapeutic agents in Alzheimer's disease through a multi-targetdirected ligands strategy: recent progress based on tacrine core
Saxena et al. The structural hybrids of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease: A review
EP2481407B1 (en) Compounds for use in treating cognitive disorders
US20080200405A1 (en) Drug Resistance Reversal In Neoplastic Disease
US20140005187A1 (en) Oxidosqualene cyclase as a protein target for anticancer therapeutics
BR112019018495A2 (pt) derivados de desmetilanetola tritiona para o tratamento de doenças relacionadas com a produção mitocondrial de espécies de oxigênio reativo (ero)
AU2004220607B2 (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system
US9889139B2 (en) Method of treating inflammatory bowel disease comprising administering a pharmaceutical composition comprising a 6-aminopyridin-3-ol compound or a pharmaceutically acceptable salt thereof as an active ingredient to a subject
AU2004317879A1 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
Ismaili et al. Multitarget-directed antioxidants as therapeutic agents: Putting the focus on the oxidative stress
US20160289187A1 (en) Hybrid compounds of curcumin and melatonin as neuroprotectants for neurodegenerative disorders
EP2970118B1 (en) Compounds for the treatment of neurological disorders
EP4103186A1 (en) Mono and combination therapies with ulk1/2 inhibitors
EA041317B1 (ru) Синергетические композиции, содержащие (r)-димирацетам (1) и (s)-димирацетам (2) в нерацемическом соотношении
CZ2008423A3 (cs) Indolonové slouceniny užitecné pri lécení kognitivní poruchy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: RICHTER GEDEON NYRT.

Free format text: FORMER OWNER(S): LIPIDART KUTATO FEJLESZTO ES TANACSADO KFT.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired